Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
What To Expect From Solventum’s (SOLV) Q4 Earnings
What To Expect From Solventum’s (SOLV) Q4 Earnings
What To Expect From Solventum’s (SOLV) Q4 Earnings
Anthony Lee
Thu, February 26, 2026 at 1:11 AM GMT+9 2 min read
In this article:
SOLV
-0.17%
Healthcare solutions provider Solventum (NYSE:SOLV) will be reporting earnings tomorrow afternoon. Here’s what investors should know.
Solventum beat analysts’ revenue expectations last quarter, reporting revenues of $2.10 billion, flat year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ organic revenue estimates.
Is Solventum a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Solventum’s revenue to decline 5.5% year on year, a reversal from the 1.9% increase it recorded in the same quarter last year.
Solventum Total Revenue
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Solventum has a history of exceeding Wall Street’s expectations.
Looking at Solventum’s peers in the surgical equipment & consumables - diversified segment, some have already reported their Q4 results, giving us a hint as to what we can expect. STERIS delivered year-on-year revenue growth of 9.2%, beating analysts’ expectations by 1.1%, and Zimmer Biomet reported revenues up 10.9%, topping estimates by 0.9%. STERIS traded down 7.7% following the results while Zimmer Biomet was up 6.6%.
Read our full analysis of STERIS’s results here and Zimmer Biomet’s results here.
Investors in the surgical equipment & consumables - diversified segment have had fairly steady hands going into earnings, with share prices down 1.9% on average over the last month. Solventum is down 5.6% during the same time and is heading into earnings with an average analyst price target of $89.25 (compared to the current share price of $74.04).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Terms and Privacy Policy
Privacy Dashboard
More Info